Drostanolone vs Stanozolol
Drostanolone (B-tier) vs Stanozolol (B-tier). mechanism, trials, claims vs data, dosing literature. side-by-side reference.
Drostanolone — tier B
a historical dromostanolone propionate breast-cancer drug with small human oncology series, no valid systemic half-life, and no current approved human product located.
the historical antitumor signal is human evidence, but it is old, small, formulation-specific, and missing the modern PK and safety limbs needed for confidence.
0 modern systemic human PK studies · half-life unknown; no qualifying systemic human or animal plasma half-life for dromostanolone propionate located · androgens
Stanozolol — tier B
a 17-alpha-alkylated DHT-derived androgen used historically as an oral tablet and injectable aqueous suspension, with controlled human lipid harm and no validated human terminal half-life.
stanozolol's strongest human evidence is a controlled demonstration of large adverse lipid changes, not a validated body-composition outcome or a human half-life.
HDL -33% in a 6-week human crossover trial · half-life no validated human terminal half-life; horse intramuscular suspension apparent terminal half-life 82.1 hours · androgens
at a glance
- Drostanolone: tier B · 0 modern systemic human PK studies
- Stanozolol: tier B · HDL -33% in a 6-week human crossover trial
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.
